NAKA vs OPRX

For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.

8% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). OptimizeRx Corporation (OPRX) offers the better valuation at 19. 7x trailing P/E (5. 6x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, OptimizeRx Corporation (OPRX) delivered a total return of -89.

8%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: OPRX returned +56. 9% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), OptimizeRx Corporation (OPRX) is the lower-risk stock at 2.

18β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately 32% more volatile than OPRX relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 20% versus 41% for Nakamoto Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.

8% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 11. 0% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — OPRX leads at 63. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OPRX: 219.

5% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, OptimizeRx Corporation (OPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OPRX: +56. 9%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAKA (Financial Services) and OPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.